The treatment of Stanford type B aortic dissection includes conservative medical treatment, endovascular aortic repair and open surgery, but the specific treatment strategy is still controversial. The onset age of Chinese patients is 10 to 20 years lower than that of European and American countries, the life expectancy is longer, and the incidence of long-term distal aortic adverse events is higher, so the treatment should be more active. In recent years, with the rapid development of thoracic endovascular aortic repair (TEVAR), it has been widely carried out in various cardiovascular centers in China because of its advantages such as small trauma, low risk, fast recovery and easy mastery of technology. TEVAR closes the larger primary rupture at the proximal end, reduces the blood flow in the false lumen, promotes the thrombosis of the false lumen and aortic remodeling, delays arterial dilation, and reduces the medium and long-term risk. Therefore, TEVAR has gradually replaced most open surgeries as one of the main treatment methods for Stanford B aortic dissection, and has now become the first choice treatment for Stanford B aortic dissection in China.
